Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel acquired 2,000 shares of the stock in a transaction dated Tuesday, April 18th. The shares were bought at an average cost of $11.12 per share, for a total transaction of $22,240.00. Following the acquisition, the chief executive officer now owns 5,279,177 shares in the company, […]
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 275,700 shares, an increase of 43.2% from the March 15th total of 192,500 shares. Currently, 7.7% of the shares of the company are short sold. Based on […]
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 192,500 shares, an increase of 9.9% from the February 28th total of 175,100 shares. Currently, 5.4% of the company’s stock are short sold. Based on an average trading volume of […]
Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Greenwich LifeSciences Inc. is a clinical stage biopharmaceutical company focuses on the development of cancer immunotherapies for breast cancer and other […]
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel purchased 4,500 shares of Greenwich LifeSciences stock in a transaction dated Thursday, June 9th. The shares were purchased at an average cost of $10.90 per share, for a total transaction of $49,050.00. Following the transaction, the chief executive officer now owns 1,243,453 shares in the […]